Prognostic significance of pT3a staging subclassifications in renal cell carcinoma: Not all pT3a are equal

被引:1
作者
Rezaee, Michael E. [1 ,2 ]
Pallauf, Maximilian [1 ,2 ,3 ]
Fletcher, Sean A. [1 ,2 ]
Pavlovich, Christian P. [1 ,2 ]
Baraban, Ezra [4 ]
Ged, Yasser [2 ]
Singla, Nirmish [1 ,2 ,5 ]
机构
[1] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21218 USA
[3] Paracelsus Med Univ, Univ Salzburg, Dept Urol, Salzburg, Austria
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21218 USA
关键词
Kidney cancer; Non-clear cell; Staging; Prognosis; Renal vein; NEPHRECTOMY; SURVIVAL; RISK;
D O I
10.1016/j.urolonc.2024.01.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To examine the prognostic significance of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a renal Methods: A population-based retrospective cohort study of patients with pT3aN0M0 RCC was performed using Surveillance, Epidemiology, and End Results (SEER) data for the years 2010 through 2019. Cox proportional hazards models were used to examine the relationship between pT3a subclassification groups and cancer-specific survival (CSS) by histological subtype (clear cell, papillary, chromophobe, Results: The cohort consisted of 10,170 patients with pT3a RCC, including 8,446 (83.0%) with clear cell RCC and 1,724 (17.0%) with nonclear cell RCC (nccRCC). Median follow up was 36 months. Differences in CSS by pT3a subclassification groups were observed in all histological subtypes but were most pronounced in nccRCC, specifically papillary RCC. Compared to perinephric fat (PF) invasion only, renal vein (RV) invasion (HR = 4.9, 95%CI: 2.5-9.3, P < 0.01), renal sinus fat invasion (HR = 3.0, 95%CI: 1.4-6.2), RV and PF invasion (HR = 7.5, 95%CI: 3.5-16.0), and combination of all three characteristics (HR = 4.4, 95%CI: 1.2-15.5) were associated with worse CSS in patients with papillary RCC. Conclusion: We examined the prognostic role of pT3a staging subclassifications in RCC by histologic subtype and observed survival differences, particularly in papillary RCC. Our findings highlight the need to refine pT3a staging criteria to help guide individualized, multimodal treatment strategies for locally advanced RCC. (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页码:119e23 / 119e29
页数:7
相关论文
共 29 条
[11]  
Haas NB, 2020, J Clin Oncol, V38, DOI [10.1200/JCO.2020.38.15_suppl.TPS5101: TPS5101TPS5101, DOI 10.1200/JCO.2020.38.15_SUPPL.TPS5101:TPS5101]
[12]   Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data [J].
Howlader, Nadia ;
Ries, Lynn A. G. ;
Mariotto, Angela B. ;
Reichman, Marsha E. ;
Ruhl, Jennifer ;
Cronin, Kathleen A. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (20) :1584-1598
[13]   Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J].
Janzen, NK ;
Kim, HL ;
Figlin, RA ;
Belldegrun, AS .
UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (04) :843-+
[14]   Independent Validation of the 2010 American Joint Committee on Cancer TNM Classification for Renal Cell Carcinoma: Results From a Large, Single Institution Cohort [J].
Kim, Simon P. ;
Alt, Angela L. ;
Weight, Christopher J. ;
Costello, Brian A. ;
Cheville, John C. ;
Lohse, Christine ;
Allmer, Cristine ;
Leibovich, Bradley C. .
JOURNAL OF UROLOGY, 2011, 185 (06) :2035-2039
[15]   Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma [J].
Lai, Gu-Shun ;
Li, Jian-Ri ;
Wang, Shian-Shiang ;
Chen, Chuan-Shu ;
Yang, Chun-Kuang ;
Hung, Sheng-Chun ;
Cheng, Chen-Li ;
Ou, Yen-Chuan ;
Chiu, Kun-Yuan .
IN VIVO, 2021, 35 (02) :1083-1089
[16]  
Malouf GG, 2017, CLIN ADV HEMATOL ONC, V15, P409
[17]   Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial [J].
Motzer, Robert J. ;
Russo, Paul ;
Gruenwald, Viktor ;
Tomita, Yoshihiko ;
Zurawski, Bogdan ;
Parikh, Omi ;
Buti, Sebastiano ;
Barthelemy, Philippe ;
Goh, Jeffrey C. ;
Ye, Dingwei ;
Lingua, Alejo ;
Lattouf, Jean-Baptiste ;
Albiges, Laurence ;
George, Saby ;
Shuch, Brian ;
Sosman, Jeffrey ;
Staehler, Michael ;
Vazquez Estevez, Sergio ;
Simsek, Burcin ;
Spiridigliozzi, Julia ;
Chudnovsky, Aleksander ;
Bex, Axel .
LANCET, 2023, 401 (10379) :821-832
[18]   Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed? [J].
Novara, Giacomo ;
Ficarra, Vincenzo ;
Antonelli, Alessandro ;
Artibani, Walter ;
Bertini, Roberto ;
Carini, Marco ;
Cunico, Sergio Cosciani ;
Imbimbo, Ciro ;
Longo, Nicola ;
Martignoni, Guido ;
Martorana, Giuseppe ;
Minervini, Andrea ;
Mirone, Vincenzo ;
Montorsi, Francesco ;
Schiavina, Roberto ;
Simeone, Claudio ;
Serni, Sergio ;
Simonato, Alchiede ;
Siracusano, Salvatore ;
Volpe, Alessandro ;
Carmignani, Giorgio .
EUROPEAN UROLOGY, 2010, 58 (04) :588-595
[19]   Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial [J].
Pal, Sumanta Kumar ;
Uzzo, Robert ;
Karam, Jose Antonio ;
Master, Viraj A. ;
Donskov, Frede ;
Suarez, Cristina ;
Albiges, Laurence ;
Rini, Brian ;
Tomita, Yoshihiko ;
Kann, Ariel Galapo ;
Procopio, Giuseppe ;
Massari, Francesco ;
Zibelman, Matthew ;
Antonyan, Igor ;
Huseni, Mahrukh ;
Basu, Debasmita ;
Ci, Bo ;
Leung, William ;
Khan, Omara ;
Dubey, Sarita ;
Bex, Axel .
LANCET, 2022, 400 (10358) :1103-1116
[20]   Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States [J].
Patel, Hiten D. ;
Gupta, Mohit ;
Joice, Gregory A. ;
Srivastava, Arnav ;
Alam, Ridwan ;
Allaf, Mohamad E. ;
Pierorazio, Phillip M. .
EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (04) :343-348